knowledge -WSS

knowledge

author：focus 2025-10-01 04:13:35 - browse：925

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Why police arrested suspected Gilgo Beach killer away from his house

WSS

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

HIPAA doesn't protect reproductive records from prosecutors

7 of the most gruesome medical devices in history

The new HIV moral panic

Does aspartame cause cancer? What new WHO guidance says

CDC backtracks, saying fully vaccinated people can go maskless indoors

Wikipedia

knowledge

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Novavax promises a turnaround & Lilly roils the obesity market

Who gets to use the title 'doctor'?

Tori Bowie and the unacceptable rates of Black maternal death

Eli Lilly to acquire Versanis in heated race for weight loss drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Can CDC director Mandy Cohen drive consensus in Washington?

Continuity nursing helped my family in our darkest PICU moments

Congress: Eradicate hepatitis C and reduce the deficit

hotspot

Caitlin Bernard's story shows physicians can't shy from advocacy

The new HIV moral panic

Europe sees delivery challenges ahead on Alzheimer's therapies

Court strikes down limits on filming of police in Arizona

The new HIV moral panic

J&J expands global access to TB drug amid advocacy campaign

focus

hotspot

hotspot

focus